{
    "clinical_study": {
        "@rank": "34978", 
        "arm_group": [
            {
                "arm_group_label": "Group S+", 
                "arm_group_type": "Experimental", 
                "description": "CMV seropositive subjects at inclusion"
            }, 
            {
                "arm_group_label": "Group S-", 
                "arm_group_type": "Experimental", 
                "description": "CMV seronegative subjects at inclusion"
            }
        ], 
        "brief_summary": {
            "textblock": "This study aims to estimate the incidence of CMV secondary infections (re-infections/\n      re-activation) and the incidence of CMV primary infections in adolescent females."
        }, 
        "brief_title": "Study to Explore CMV Infection in Adolescent Girls", 
        "completion_date": {
            "#text": "March 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Infections, Cytomegalovirus", 
        "condition_browse": {
            "mesh_term": "Cytomegalovirus Infections"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  A female adolescent between, and including 10 and 17 years at the time of enrolment\n             regardless of pregnancy status and contraception method used or not used.\n\n          -  Subjects who the investigator believes that the subject and/or the subject's\n             parent(s)/Legally Acceptable Representative(s) (LAR[s]) can and will comply with the\n             requirements of the protocol.\n\n          -  Written informed assent and/or consent obtained from the subject and/or the\n             parent(s)/LAR(s) of the subject.\n\n          -  Subject is likely to remain in the area and/or return for required study Site Visits\n             and complete Sample Collection Visits.\n\n        Exclusion Criteria:\n\n          -  Child in care.\n\n          -  Use or planned use of any investigational or non-registered antiviral drug or vaccine\n             during the study period.\n\n          -  Known medical history of any recurrent clinical herpes episodes requiring episodic or\n             chronic suppressive treatment with oral or parenteral antiviral treatment such as\n             acyclovir, famciclovir, valacyclovir or any other anti-herpes virus anti-viral during\n             the year preceding enrolment. Topical anti-viral are allowed.\n\n          -  Subjects with history of previous vaccination against CMV.\n\n          -  Chronic administration of immunosuppressants or other immune-modifying drugs within 6\n             months prior to Visit 1 or planned administration during the study. Inhaled and\n             topical steroids are allowed.\n\n          -  Administration of immunoglobulins and/or any blood products within 3 months prior to\n             Visit 1 or planned administration during the study.\n\n          -  Any confirmed or suspected immunosuppressive or immunodeficient condition including\n             HIV-infection, based on medical history and physical examination (no laboratory\n             testing required).\n\n          -  Any major congenital defects, serious chronic illness or organ transplantation."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "17 Years", 
            "minimum_age": "10 Years"
        }, 
        "enrollment": {
            "#text": "384", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01691820", 
            "org_study_id": "115639"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group S-", 
                    "Group S+"
                ], 
                "description": "Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.", 
                "intervention_name": "Blood collection", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Group S-", 
                    "Group S+"
                ], 
                "description": "Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.", 
                "intervention_name": "Urine collection", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Group S-", 
                    "Group S+"
                ], 
                "description": "Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.", 
                "intervention_name": "Dry urine collection", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Group S-", 
                    "Group S+"
                ], 
                "description": "Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.", 
                "intervention_name": "Saliva collection", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Group S-", 
                    "Group S+"
                ], 
                "description": "Samples collected upon delivery or within 10 days of delivery.", 
                "intervention_name": "Urine and/ or saliva collection from newborn in case of pregnancy", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Adolescent females", 
            "Cytomegalovirus (CMV)"
        ], 
        "lastchanged_date": "April 24, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35233"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stevensville", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "49127"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Helsinki", 
                        "country": "Finland", 
                        "zip": "00100"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oulu", 
                        "country": "Finland", 
                        "zip": "90220"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jojutla / Morelos", 
                        "country": "Mexico"
                    }, 
                    "name": "GSK Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Finland", 
                "Mexico"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Study in Adolescent Females to Explore Cytomegalovirus Infection", 
        "overall_official": {
            "affiliation": "GlaxoSmithKline", 
            "last_name": "GSK Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Finland: Ministry of Social Affairs and Health", 
                "Mexico: Comision Federal para la Proteccion contra Riesgos Sanitarios (COFEPRIS)", 
                "Brazil: Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (ANVISA)"
            ]
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Occurrence of CMV secondary infections determined in all seropositive subjects in terms of antibody concentrations and viral load.", 
                "safety_issue": "No", 
                "time_frame": "Every 4 months from Month 0 to Month 36"
            }, 
            {
                "measure": "Occurrence of CMV primary infections determined in all seronegative subjects in terms of antibody concentrations.", 
                "safety_issue": "No", 
                "time_frame": "Every 4 months from Month 0 to Month 36"
            }
        ], 
        "removed_countries": {
            "country": "Brazil"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01691820"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "GlaxoSmithKline", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "GlaxoSmithKline", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}